New insight in LPS antagonist

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 3, 2009, Pages 306-317

  Ianaro, A ^a   Tersigni, M ^a   D'Acquisto, F ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Innate immunity; Lipid A; Lipopolysaccharide; Sepsis; Toll like receptor 4

Indexed keywords

6 [N (2 CHLORO 4 FLUOROPHENYL)SULFAMOYL] 1 CYCLOHEXENE 1 CARBOXYLIC ACID ETHYL ESTER; ANTIINFLAMMATORY AGENT; BACTERIUM LIPOPOLYSACCHARIDE; BESIFLOXACIN; CD200 ANTIGEN; CRX 526; CYP; LIPID A; LIPID A DERIVATIVE; LIPOPOLYSACCHARIDE; MOXIFLOXACIN; PROTEIN LP17; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOLL LIKE RECEPTOR 4; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; UNCLASSIFIED DRUG; DRUG DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL THERAPY; CAPNOCYTOPHAGA; CARBOHYDRATE ANALYSIS; COLITIS; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; NONHUMAN; PORPHYROMONAS GINGIVALIS; REVIEW; RHODOBACTER CAPSULATUS; SEPSIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; PHYSIOLOGY;

ANIMALS; HUMANS; LIPID A; LIPOPOLYSACCHARIDES; MOLECULAR STRUCTURE; SEPSIS; SIGNAL TRANSDUCTION;

EID: 65349186058     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557510909030306     Document Type: Review

References (100)

1. Cohen, J. The immunopathogenesis of sepsis. Nature, 2002, 420, 885-91.
2. Martin, G.S.; Mannino, D.M.; Eaton, S.; Moss, M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med., 2003, 348, 1546-54.
3. Angus, D.C.; Linde-Zwirble, W.T.; Lidicker, J.; Clermont, G.; Carcillo, J.; Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med., 2001, 29, 1303-10.
4. O'Brien, J.M. Jr; Ali, A.A; Aberegg, S.K.; Abraham, E. Sepsis. Am J. Med., 2007, 120, 1012-22.
5. Marshall, J.C. Sepsis: current status, future prospects. Curr. Opin. Crit. Care, 2004, 10, 250-64.
6. Tobias, P.S.; Soldau, K.; Ulevitch, R.J. Isolation of a lipopolysac-charide-binding acute phase reactant from rabbit serum. J. Exp. Med., 1986, 164, 777-93.
7. Wright, S.D.; Tobias, P.S.; Ulevitch, R.J.; Ramos, R.A. Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages. J. Exp. Med., 1989, 170, 1231-41.
8. Kitchens, R.L.; Munford, R.S. CD14-dependent internalization of bacterial lipopolysaccharide (LPS) is strongly influenced by LPS aggregation but not by cellular responses to LPS. J. Immunol., 1998, 160, 1920-8.
9. Haziot, A.; Chen, S.; Ferrero, E.; Low, M.G.; Silber, R.; Goyert, S.M. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J. Immunol., 1988, 141, 547-52.
10. Kitchens, R.L. Role of CD14 in cellular recognition of bacterial lipopolysaccharides. Chem. Immunol. 2000, 74, 61-82.
11. Medzhitov, R.; Preston-Hurlburt, P.; Janeway, C.A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 1997, 388, 394-7.
12. Poltorak, A.; He, X.; Smirnova, I.; Liu, M. Y.; Huffel, C. V.; Du, X.; Birdwell, D.; Alejos, E.; Silva, M.; Galanos, C.; Freudenberg, M.; Ricciardi-Castagnoli, P.; Layton, B.; Beutler, B. Defective LPS signalling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science, 1998, 282, 2085-8.
13. Chow, J.C.; Young, D.W.; Golenbock, D.T.; Christ, W.J.; Gusovsky, F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem., 1999, 274, 10689-92.
14. Akashi, S.; Shimazu, R.; Ogata, H.; Nagai, Y.; Takeda, K.; Kimoto, M.; Miyake, K. Cutting edge: cell surface expression and lipopolysaccharide signalling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J. Immunol., 2000, 164, 3471-5.
15. Shimazu, R.; Akashi, S.; Ogata, H.; Nagai, Y.; Fukudome, K.; Miyake, K.; Kimoto, M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp.Med., 1999, 189, 1777-82.
16. Akashi, S.; Ogata, H.; Kirikae, F.; Kirikae, T.; Kawasaki, K.; Nishijima, M.; Shimazu, R.; Nagai, Y.; Fukudome, K.; Kimoto, M.; Miyake, K. Regulatory roles for CD14 and phosphatidylinositol in the signalling via toll-like receptor 4-MD-2. Biochem. Biophys. Res. Commun., 2000, 268, 172-7.
17. Yang, H.; Young, D.W.; Gusovsky, F.; Chow, J.C. Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4. MD-2 is required for activation of mitogen-activated protein kinases and Elk-1. J. Biol. Chem., 2000, 275, 20861-6.
18. Westphal, O. Luderitz, O. Chemische erforschung von lipopolysacchariden gram-negativer bakterien. Angew. Chem., 1954, 66, 407-417.
19. Galanos, C.; Luderitz, O.; Rietschel, E.T.; Westphal, O.; Brade, H.; Brade, L.; Freudenberg, M.; Schade, U.; Imoto, M.; Yoshimura, H. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur. J. Biochem., 1985, 148, 1-5.
20. Loppnow, H.; Libby, P.; Freudenberg, M.; Krauss, J.H.; Weckesser, J.; Mayer, H. Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect. Immun., 1990, 58, 3743-50.
21. Golenbock, D.T.;, Hampton, R.Y.; Qureshi, N.; Takayama, K.; Raetz, C.R. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J. Biol. Chem., 1991, 266, 19490-8.
22. Ialenti, A.; Di Meglio, P.; Grassia, G.; Maffia, P.; Di Rosa, M.; Lanzetta, R.; Molinaro, A.; Silipo, A.; Grant, W.; Ianaro, A. A novel lipid A from Halomonas magadiensis inhibits enteric LPS-induced human monocyte activation. Eur. J. Immunol., 2006 36, 354-60.
23. Kenakian, T. P. Comprehensive Medicinal Chemistry, The Rational Design, Mechanistic Study & Therapeutic Appication of Chemical Compounds; Pergamon Press: New York, 1990; pp. 195-203.
24. Macagno, A.; Molteni, M; Rinaldi, A; Bertoni, F; Lanzavecchia, A.; Rossetti, C.; Sallusto, F. Cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. J. Exp. Med., 2006, 203, 1481-92.
25. Keleti, G.; Sykora, J.L. 1982. Production and properties of cyanobacterial endotoxins. Appl. Environ. Microbiol., 1982, 43, 104-09.
26. Jemmett, K.; Macagno, A.; Molteni, M.; Heckels, J.E.; Rossetti, C.; Christodoulides, M. A cyanobacterial lipopolysaccharide antagonist inhibits cytokine production induced by Neisseria meningitidis in a human whole-blood model of septicemia. Infect. Immun. 2008, 76, 3156-63.
27. Thorgersen, E.B.; Macagno, A.; Rossetti, C.; Mollnes, T.E. Cyanobacterial LPS antagonist (CyP)-A novel and efficient inhibitor of Escherichia coli LPS-induced cytokine response in the pig. Mol. Immunol., 2008, 45, 3553-57.
28. Strittmatter, W.; Weckesser J., Salimath P.V.; Galanos C. 1983. Nontoxic lipopolysaccharide from Rhodopseudomonas sphaeroides ATCC 17023. J. Bacteriol., 1983, 155, 153-58.
29. Hollingsworth, R.I.; Carlson, R.W. 27-Hydroxyoctacosanoic acid is a major structural fatty acyl component of the LPS of Rhizobium trifolii ANU 843. J. Biol. Chem., 1989, 264, 9300-03.
30. Urbanik-Sypniewska, T.; Seydel, U.; Greck, M.; J. Weckesser, J.; Mayer, H. Chemical studies on the lipopolysaccharide of Rhizobium meliloti. Arch. Microbiol., 1989, 152, 527-32.
31. Loppnow, H.; Libby, P. Comparative analysis of cytokine induction in human vascular endothelial and smooth muscle cells. Lymphokine Res., 1989, 8, 293-99.
32. Takayama, K.; Qureshi, N.; Beutler, B.; Kirkland, T.N. Diphosphoryl lipid A from Rhodopseudomonas sphaeroides ATCC 17023 blocks induction of cachectin in macrophages by lipopolysaccharide. Infect. Immun., 1989, 57, 1336-38.
33. Kovach, N.L.; Yee, E.; Munford, R.S.; Raetz, C.R.H.; Harlan, J.M. Lipid IVa inhibits synthesis and release of tumor necrosis factor induced by lipopolysaccharide in human blood ex vivo. J. Exp. Med., 1990, 172, 77-84.
34. Lepper, P.M.; Triantafilou, M.; Schumann, C.; Schneider, E.M.; Triantafilou, K. Lipopolysaccharides from Helicobacter pylori can act as antagonists for Toll-like receptor 4. Cell. Microbiol., 2005, 7, 519-28.
35. Kawahara, T.; Kuwano, Y.; Teshima-kondo, S.; Kawai, T.; Nikawa, T.; Kishi, K.; Rokutan, K. Toll-like receptor 4 regulates gastric pit cell responses to Helicobacter pylori infection. J. Med. Invest., 2001, 48, 190-97.
36. Kawahara, T.; Teshima, S.; Oka, A.; Sugiyama, T.; Kishi, K.; Rokutan, K. Type I Helicobacter pylori lipopolysaccharide stimulates Toll-like receptor 4 and activates mitogen oxidase 1 in gastric pit cells. Infect. Immun., 2001, 69, 4382-89.
37. Smith, M.F.; Mitchell, A.; Li, G.; Ding, S.; Fitzmaurice, A.M.; Ryan, K. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-κB activation and chemokine expression by epithelial cells. J. Biol. Chem., 2003, 278, 32552-560.
38. Moran, A.P.; Helander, I.M.; Kosunen, T.U. Compositional analysis of Helicobacter pylori rough form lipopolysaccharides. J. Bacteriol., 1992, 174, 1370-77.
39. Moran, A.P. Cell surface characteristics of Helicobacter pylori. FEMS Immunol. Med. Microbiol., 1995, 10, 271-80.
40. Moran, A.P.; Helander, I.M.; Kosunen, T.U. Compositional analysis of Helicobacter pylori rough form lipopolysaccharides. J. Bacteriol., 1992, 174, 1370-77.
41. Moran, A.P.; Lindner, B.; Walsh, E.J. Structural characterization of the lipid A component of Helicobacter pylori rough- and smooth-form lipopolysaccharides. J. Bacteriol., 1997, 179, 6453-63.
42. Schromm, A.; Bradenburg, K.; Loppnow, H.; Moran, A.P.; Koch, M.H.J.; Rietschel, E.; Seydel, U. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. Eur. J. Biochem., 2000, 267, 2008-13.
43. Hirschfeld, M.; Weis, J.J.; Toshchakov, V.; Salkowski, C.A.; Cody, M.J.; Watts, D.C. Signalling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect. Immun., 2001, 69, 1477-82.
44. Yoshimura, A.; Kaneko, T.; Kato, Y.; Golenbock, D.T.; Hara, Y. Lipopolysaccharides from periodontopathic bacteria Porphyromonas gingivalis and Capnocytophaga ochracea are antagonists for human toll-like receptor. Infect. Immun., 2002, 70, 218-25.
45. Hirschfeld, M.; Kirschning, C.J.; Schwandner, R.; Wesche, H.; Weis, J.H.; Wooten, R.M; Weis, J.J. Cutting edge: inflammatory signalling by Borrelia burgdorferi lipoproteins is mediated by Toll-like receptor 2. J. Immunol., 1999, 163, 2382-86.
46. Kumada, H.; Haishima, Y.; Umemoto, T.; Tanamoto, K. Structural study on the free lipid A isolated from lipopolysaccharide of Porphyromonas gingivalis. J. Bacteriol., 1995, 177, 2098-2106.
47. Ogawa, T. Chemical structure of lipid A from Porphyromonas (Bacteroides) gingivalis lipopolysaccharide. FEBS Lett., 1993, 332, 197-201.
48. Ogawa, T.; Uchida, H. Differential induction of IL-1β and IL-6 production by the nontoxic lipid A from Porphyromonas gingivalis in comparison with synthetic Escherichia coli lipid A in human peripheral blood mononuclear cells. FEMS Immunol. Med. Microbiol., 1996, 14, 1-13.
49. Tabeta, K.; Yamazaki, K.; Akashi, S.; Miyake, K.; Kumada, H.; Umemoto, T.; Yoshie, H. Toll-like receptors confer responsiveness to lipopolysaccharide from Porphyromonas gingivalis in human gingival fibroblasts. Infect. Immun., 2000, 68, 3731-35.
50. Wang, P.L.; Azuma, Y.; Shinohara, M.; Ohura, K. Toll-like receptor 4-mediated signal pathway induced by Porphyromonas gingivalis lipopolysaccharide in human gingival fibroblasts. Biochem. Biophys. Res. Commun., 2000, 273, 1161-67.
51. Fort, M.M.; Mozaffarian, A.; Stöver, A.G.; Correia, J. da S.; Johnson, D.A.; Crane, R.T.; Ulevitch, R.J.; Persing, D.H.; Bielefeldt-Ohmann, H.; Probst, P.; Jeffery, E.; Fling, S.P.; Hershberg, R.M. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine modes of inflammatory bowel disease. J. Immunol., 2005, 174, 6416-23.
52. Gorczynski, R.; Boudakov, I.; Khatri, I. Peptides of CD200 modulate LPS-induced TNF-alpha induction and mortality in vivo. J. Surg. Res., 2008, 145, 87-96.
53. Zhang, S.; Phillips, J.H. Identification of tyrosine residues crucial for CD200R-mediated inhibition of mast cell activation. J. Leukoc. Biol., 2006, 79, 363-68.
54. Gorczynski, R.M.; Chen, Z.Q.; Yu, K.; Hu, J. CD200 immunoadhesin suppresses collagen-induced arthritis in mice. Clin. Immunol., 2001, 101, 328-34.
55. Gorczynski, R.M.; Chen, Z.; Fu, X.M. Increased expression of the novel molecule Ox-2 is involved in prolongation of murine renal allograft survival. Transplantation, 1998, 65, 1106-14.
56. Hoek, R.M.; Ruuls, S.R.; Murphy, C.A.; Wright, G.J.; Goddard, R.; Zurawski, S.M.; Blom, B.; Homola, M.E.; Streit, W.J.; Brown, M.H.; Barclay, A.N.; Sedgwick, J.D. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science, 2000, 290, 1768-71.
57. Neumann, H. Control of glial immune function by neurons. Glia, 2001, 36, 191-99.
58. Dick, A.D.; Cheng, Y.F.; Liversidge, J. Immunomodulation of experimental autoimmune uveoretinitis: A model of tolerance induction with retinal antigens. Eye, 2004, 8, 52-9.
59. Taylor, N.; McConnachie, K.; Calder, C.; Dawson, R.; Dick, A.; Sedgwick, J.D.; Liversidge, J. Enhanced tolerance to autoimmune uveitis in CD200-deficient mice correlates with a pronounced Th2 switch in response to antigen challenge. J. Immunol., 2005, 174, 143-54.
60. Shiratori, I.; Yamaguchi, M.; Suzukawa, M.; Yamamoto, K.; Lanier, L.L.; Saito, T.; Arase, H. Down-regulation of basophil function by human CD200 and human herpesvirus-8 CD200. J. Immunol., 2005, 175, 4441-49.
61. Foster-Cuevas, M.; Wright, G.J.; Puklavec, M.J.; Brown, M.H.; Barclay, A.N. Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor. J. Virol., 2004, 78, 7667-76.
62. Brunn, G.J.; Platt, J.L. The etiology of sepsis: Turned inside out. Trends Mol. Med., 2006, 12, 10-6.
63. Hatherley, D.; Barclay, A.N. The CD200 and CD200 receptor cell surface proteins interact through their N-terminal immunoglobulin-like domains. Eur. J. Immunol., 2004, 34, 1688-94.
64. Bouchon, A.; Dietrich, J.; Colonna, M. Inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J. Immunol., 2000, 164, 4991-95.
65. Colonna, M. TREMs in the immune system and beyond. Nat. Rev. Immunol., 2003, 3, 445-53.
66. Bouchon, A.; Facchetti, F.; Weigand, M.A.; Colonna, M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature, 2001, 410, 1103-07.
67. Bleharski, J.R.; Kiessler, V.; Buonsanti, C.; Sieling, P.A.; Stenger, S.; Colonna, M.; Modlin, R.L. A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response. J. Immunol., 2003, 170, 3812-18.
68. Gibot, S.; Kolopp-Sarda, M.N.; Bene, M.C.; Bollaert, P.E.; Lozniewski, A.; Mory, F.; Levy, B.; Faure, G.C. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J. Exp. Med., 2004, 200, 1419-26.
69. Radaev, S.; Kattah, M.; Rostro, B.; Colonna, M.; Sun, P. Crystal structure of the human myeloid cell activating receptor TREM-1. Structure, 2003, 11, 1527-35.
70. Lantz, M.; Gullberg, U.; Nilsson, E. Characterization in vitro of a human tumor necrosis factor binding protein. A soluble form of tumor necrosis factor receptor. J. Clin. Invest., 1990, 86, 1396-01.
71. van Zee, K.J.; Kohno, T.; Fischer, E. Tumor necrosis soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor β in vitro and in vivo. Proc. Natl. Acad. Sci. USA., 1992, 89, 4845-53.
72. Collart, M.A.; Baeuerle, P.; Vassalli, P. Regulation of tumor necrosis factor alpha transcription in macrophages. Involvement of four NFκB motifs and constitutive and inducible form of NFκB. Mol. Cell. Biol., 1990, 10, 1498-06.
73. Urban, M.B.; Schreck, R.; Baeuerle, P.A. NFκB contacts DNA by a heterodimer of the p50 and p65 subunit. EMBO J., 1991, 10, 1817-25.
74. Dinarello, C.A. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest, 1997, 112, S321-S329.
75. Bone, R.C.; Balk, R.A.; Cerra, F.B.; Dellinger, R.P.; Fein, A.M.; Knauss, W.A.; Schein, R.M; Sibbald, W.J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest, 1992, 101, 1644-55.
76. Hotchkiss, R.S.; Karl, I.E. The pathophysiology and treatment of sepsis. N. Engl. J. Med., 2003, 348, 138-50.
77. Gibot, S.; Massin, F.; Marcou, M.; Taylor, V.; Stidwill, R.; Wilson, P.; Singer, M.; Bellingan, G. TREM-1 promotes survival during septic shock in mice. Eur. J. Immunol., 2007, 37, 456-66.
78. Yamada, M.; Ichikawa, T.; Ii, M.; Sunamoto, M.; Itoh, K.; Tamura, N.; Kitazaki, T. Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl) cyclohex-1-ene-1-carboxylate. J. Med. Chem., 2005, 48, 7457-67.
79. Sha, T.; Sunamoto, M.; Kitazaki, T.; Sato, J.; Ii, M.; Iizawa, Y. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur. J. Pharmacol., 2007, 571, 231-39.
80. Ii, M.; Matsunaga, N.; Hazeki, K.; Nakamura, K.; Takashima, K.; Seya, T.; Hazeki, O.; Kitazaki, T.; Iizawa, Y. A novel cyclohexene derivative, TAK-242, selectively inhibits Toll-like receptor 4-mediated cytokine production through suppression of intracellular signalling. Mol. Pharmacol., 2006, 69, 1288-95.
81. Qureshi, S.T.; Lariviere, L.; Leveque, G.; Clermont, S.; Moore, K.J.; Gros, P.; Malo, D. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med., 1999, 189, 615-25.
82. Nagai, Y.; Akashi, S.; Nagafuku, M.; Ogata, M.; Iwakura, Y.; Akira, S.; Kitamura, T.; Kosugi, A.; Kimoto, M.; Miyake, K. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol., 2002, 3, 667-72.
83. Yamamoto, M.; Sato, S.; Mori, K.; Hoshino, K.; Takeuchi, O.; Takeda, K.; Akira, S. A novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signalling. J. Immunol., 2002, 169, 6668-72.
84. Saitoh, S.; Akashi, S.; Yamada, T.; Tanimura, N.; Matsumoto, F.; Fukase, K.; Kusumoto, S.; Kosugi, A.; Miyake, K. Ligand-dependent Toll-like receptor 4 (TLR4)-oligomerization is directly linked with TLR4-signalling. J. Endotoxin Res., 2004, 10, 257-60.
85. Akashi, S.; Saitoh, S.; Wakabayashi, Y.; Kikuchi, T.; Takamura, N.; Nagai, Y.; Kusumoto, Y.; Fukase, K.; Kusumoto, S.; Adachi, Y.; Kosugi, A.; Miyake, K. Lipopolysaccharide interaction with cell surface toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J. Exp. Med., 2003, 198, 1035-42.
86. McGettrick, A.F.; Brint, E.K.; Palsson-McDermott, E.M.; Rowe, D.C.; Golenbock, D.T.; Gay, N.J.; Fitzgerald, K.A.; O'Neill, L.A. Trif-related adaptor molecule is phosphorylated by PKCε during Toll-like receptor 4 signalling. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 9196-01.
87. Medvedev, A.E.; Piao, W.; Shoenfelt, J.; Rhee, S.H.; Chen, H.; Basu, S.; Wahl, L.M.; Fenton, M.J.; Vogel, S.N. Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance. J. Biol. Chem., 2007, 282, 16042-53.
88. Zhang, J.Z.; Ward, K.W. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J. Antimicrob. Chemother., 2008, 61, 111-16.
89. Weiss, T; Shalit, I; Blau, H; Werber, S; Halperin, D; Levitov, A; Fabian, I. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-κB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob. Agents Chemother., 2004, 48, 1974-82.
90. Yang, C.S.; Ko, S.R.; Cho, B.G.; Shin, D.M.; Yuk, J.M.; Li, S.; Kim, J.M.; Evans, R.M.; Jung, J.S.; Song, D.K.; Jo, E.K. The Ginsenoside Metabolite Compound K, a Novel Agonist of Glucocorticoid Receptor, Induces Tolerance to Endotoxin-induced Lethal Shock. J. Cell. Mol. Med., 2007, "Postprint";10.1111/ j.1582-4934.2007.00181.x
91. Ogawa, S.; Lozach, J.; Benner, C.; Pascual, G.; Tangirala, R.K.; Westin, S.; Hoffmann, A.; Subramaniam, S.; David, M.; Rosenfeld, M.G.; Glass, C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell, 2005, 122, 707-21.
92. De Bosscher, K.; Vanden Berghe, W.; Haegeman, G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev., 2003, 24, 488-522.
93. Christ, W.J., Asano, O., Robidoux, A.L., Perez, M., Wang, Y., Dubuc, G.R., Gavin, W.E., Hawkins, L.D., McGuinness, P.D., Mullarkey, M.A. E5531, a pure endotoxin antagonist of high potency. Science, 1995, 268, 80-83.
94. Rose, J.R., Mullarkey, M.A., Christ, W.J., Hawkins, L.D., Lynn, M., Kishi, Y., Wasan, K.M,, Peteherych, K., Rossignol, D.P. Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins. Antimicrob. Agents Chemother., 2000, 44, 504-510.
95. Mullarkey, M., Rose, J.R., Bristol, J., Kawata, T., Kimura, A., Kobayashi, S., Przetak, M., Chow, J., Gusovsky, F., Christ, W.J., Rossignol, D.P. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther., 2003, 304, 1093-1102.
96. Savov, J.D., Brass, D.M., Lawson, B.L., McElvania-Tekippe, E., Walker, J.K., Schwartz, D.A. Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopoly-saccharide. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2005, 289, L329.
97. http://www.ClinicalTrials.gov
98. Dunn, D.L. Gram-negative bacterial sepsis and sepsis syndrome. Surg. Clin. North. Am., 1994, 74, 621-35.
99. Redecke, V., Häcker, H., Datta, S.K., Fermin, A., Pitha, P.M., Broide, D.H., Raz, E. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J. Immunol., 2004, 172, 2739-2743.
100. Elovitz, M.A., Wang, Z., Chien, E.K., Rychlik, D.F., Phillippe, M. A new model for inflammation-induced preterm birth: the role of platelet-activating factor and Toll-like receptor-4. Am. J. Pathol., 2003, 163, 2103-11.